文献速递角膜与眼表疾病

无水环孢素滴眼液与赋形剂治疗干眼病:一项随机临床试验

Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease: A Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2024-01-01

这项多中心、双盲、赋形剂对照的3期随机临床试验在中国12家医院纳入206例中重度干眼病患者,评估0.1%无水环孢素滴眼液与赋形剂的疗效和安全性。第29天时,环孢素组总角膜荧光素染色评分较基线下降4.8,赋形剂组下降3.0,组间差异为-1.8(95%CI,-2.7至-1.0;P<.001);但干涩评分(VAS)两组间差异无统计学显著性(-19.2 vs -15.4;Δ=-3.8;95%CI,-9.2至1.6;P=.17)。

要点

  • 第29天总角膜荧光素染色评分环孢素组较基线下降4.8,赋形剂组下降3.0,组间差异-1.8(95%CI,-2.7至-1.0;P<.001)。
  • 干涩评分(VAS)环孢素组下降19.2,赋形剂组下降15.4,组间差异-3.8(95%CI,-9.2至1.6;P=.17),未达统计学显著。
  • 治疗相关不良事件环孢素组15例(14.6%),赋形剂组11例(10.7%)。

核心结论

  • 0.1%无水环孢素滴眼液在改善中国干眼病患者第29天总角膜荧光素染色评分方面优于赋形剂,但干涩评分(VAS)在第29天未获改善。

研究设计与样本

  • 多中心、双盲、赋形剂对照的3期随机临床试验,于2021年3月4日至2022年7月22日在中国12家医院招募中重度干眼病成人患者,共纳入206例(平均[SD]年龄47.8[14.2]岁;女性185例[90%]),环孢素组与赋形剂组各103例。

主要发现

  • 第29天,环孢素组总角膜荧光素染色评分较基线下降4.8,赋形剂组下降3.0,组间差异为-1.8(95%CI,-2.7至-1.0;P<.001)。
  • 第29天,干涩评分(VAS)环孢素组较基线下降19.2,赋形剂组下降15.4,组间差异为-3.8(95%CI,-9.2至1.6;P=.17)。
  • 29天治疗期间,治疗相关不良事件在环孢素组报告15例(14.6%),赋形剂组报告11例(10.7%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Dry eye disease (DED) is a prevalent eye disorder. Cyclosporine is an effective immunomodulator that is widely used in DED; however, due to its highly hydrophobic nature, delivery of cyclosporine to the ocular surface is challenging. OBJECTIVE: To evaluate the efficacy and safety of SHR8028, a water-free cyclosporine ophthalmic solution, 0.1%, compared with vehicle in Chinese participants with DED. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, double-blind, vehicle-controlled, phase 3 randomized clinical trial conducted from March 4, 2021, to July 22, 2022. Adult participants with moderate to severe DED were recruited from 12 hospitals in China. Study data were analyzed April 2, 2022, for the primary analysis. INTERVENTIONS: Following a 14-day run-in period with an artificial tear, participants were randomly assigned (1:1) to receive water-free cyclosporine or vehicle (1 eye drop in each eye twice daily). After a 29-day treatment, participants of both groups were given the option to receive water-free cyclosporine for an additional 12 weeks for longer-term safety assessment. MAIN OUTCOMES AND MEASURES: The primary end points were changes from baseline in total corneal fluorescein staining (tCFS) using the National Eye Institute scale and in dryness score on a visual analog scale at day 29. RESULTS: A total of 206 participants (mean [SD] age, 47.8 [14.2] years; 185 female [90%]) were enrolled, with 103 each in the cyclosporine group and the vehicle group. At day 29, the cyclosporine group experienced improved tCFS compared with vehicle (change [Δ] = -1.8; 95% CI, -2.7 to -1.0; P < .001), with a tCFS score decrease from baseline of -4.8 in the cyclosporine group and -3.0 in the vehicle group. Dryness score decreased from baseline in both groups (-19.2 vs -15.4; Δ = -3.8; 95% CI, -9.2 to 1.6; P = .17). During the 29-day treatment, treatment-related adverse events were reported in 15 participants (14.6%) in the cyclosporine group and 11 participants (10.7%) in the vehicle group. CONCLUSIONS AND RELEVANCE: Results demonstrated superiority of a water-free cyclosporine, 0.1%, eye solution over vehicle in improving tCFS score at day 29 in Chinese participants with DED. However, dryness score (VAS) was not improved at day 29. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05841043.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Peng R, Jie Y, Long Q, et al. Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease: A Randomized Clinical Trial. JAMA Ophthalmol. 2024. PMID: 38451509. doi:10.1001/jamaophthalmol.2024.0101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。